Tempest Therapeutics Strikes $5 Million-Per-Year R&D Services MSA With Factor Bioscience

Tempest Therapeutics entered into a Master Services Agreement with Factor Bioscience to support research and development, including an initial work order focused on in vivo CAR-T therapies. The agreement contemplates aggregate fees of $5.0 million per year, paid monthly, plus reimbursement of mater…